Latest Janssen Pharmaceuticals Inc. Stories
ORLANDO, Fla., May 21, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from the global Phase 3 PROMISE study demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 79 percent of treatment-experienced genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis,...
LA JOLLA, Calif., May 7, 2013 /PRNewswire-USNewswire/ -- The Scripps Research Institute (TSRI) today announced a five-year agreement with Janssen Pharmaceuticals, Inc. (Janssen) to collaborate on focused research projects in the infectious disease area, with the initial project targeting the influenza virus. Under the agreement Janssen will receive certain license rights to the results of the research. Janssen Pharmaceuticals will collaborate in the research on influenza through its...
INVOKANA(TM) is the first in a new class of type 2 diabetes medications available in the United States RARITAN, N.J., March 29, 2013 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved INVOKANA(TM) (canagliflozin) for the treatment of adults with type 2 diabetes. INVOKANA(TM) is the first in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors to be approved in the United States. It...
Need for new treatment options and lack of patient awareness of disease impact on heart, kidneys, and pancreas among major challenges RARITAN, N.J., March 14, 2013 /PRNewswire/ -- A new, national survey revealed physicians feel type 2 diabetes patients could better manage their disease by appreciating the benefits of "small successes" - such as walking instead of driving short distances - rather than focusing on drastic changes. In fact, 97 percent of physicians said type 2 diabetes...
RARITAN, N.J., Feb. 5, 2013 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) today announced a clinical collaboration agreement with Portola Pharmaceuticals, Inc. and Bayer HealthCare to evaluate the safety of PRT4445 - an investigational-stage antidote for Factor Xa inhibitors - in healthy volunteers who have been administered the oral anticoagulant XARELTO(®) (rivaroxaban). The study will evaluate several dosage strengths of PRT4445 and its ability to reverse the...
ZURICH-SCHLIEREN, Switzerland, Jan. 4, 2013 /PRNewswire/ -- GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced that Janssen Pharmaceuticals, Inc. (JPI), has signed an exclusive license agreement and entered into a three-year research and development collaboration to develop a multi-valent bacterial vaccine employing GlycoVaxyn's bio-conjugation technology. "Bacterial pathogens that exist in multiple pathogenic strains pose significant challenges for...
SOUTH SAN FRANCISCO, Calif., Jan. 3, 2013 /PRNewswire/ -- NGM Biopharmaceuticals, Inc. announced today that it has signed a worldwide agreement with Janssen Pharmaceuticals, Inc. to discover and develop novel therapeutics for the potential treatment of Type 2 diabetes and other metabolic diseases. NGM and Janssen will jointly conduct research on selected protein factors discovered by NGM using its diabetes discovery platform, with the goal of advancing drug candidates that mimic...
NES ZIONA, Israel, November 29, 2012 /PRNewswire/ -- NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for MicronJet(R), its microneedle delivery device, with Janssen Pharmaceuticals, Inc. (JPI) for multiple vaccine fields. The license agreement will provide Janssen with an exclusive license to use the device in its seasonal influenza programs and options for...
BOSTON, Nov. 10, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) today announced that the use of one once-daily pill of the investigational protease inhibitor simeprevir (TMC435) administered with pegylated interferon and ribavirin led to higher rates of sustained viral response at 24 weeks (SVR24) compared to placebo in patients with Metavir scores of F3 and F4 who were treatment naive and treatment experienced with genotype 1 hepatitis C. Simeprevir was also generally...
RARITAN, N.J., Nov. 2, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) today announced the U.S. Food and Drug Administration (FDA) has approved XARELTO(®) (rivaroxaban), an oral anticoagulant, for the treatment of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and PE following initial treatment. To view the multimedia assets associated with this release, please click:...
